TY - JOUR
T1 - Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE)
T2 - First report and review of literature
AU - Piamsomboon, Surintip
AU - Kudelka, Andrzej P.
AU - Termrungruanglert, Wichai
AU - Van Besien, Koen
AU - Edwards, Creyhton L.
AU - Lifshitz, Samuel
AU - Schomer, Donald F.
AU - Champlin, Richard
AU - Mante, Rosario P.
AU - Kavanagh, John J.
AU - Verschraegen, Claire F.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1997
Y1 - 1997
N2 - Gestational trophoblastic disease (GTD) metastatic to the brain has a very poor prognosis with a survival rate of less than 25%, especially for patients in whom brain metastases develop while on or after chemotherapy. Cure can be achieved by chemotherapy alone. The regimen of etoposide, methotrexate, actinomycin-D, vincristine, and cyclophosphamide has shown encouraging results and is considered to be standard first-line treatment for high risk patients. For patients in whom this regimen fails, a salvage chemotherapy regimen is used. The combination of ifosfamide, carboplatin, and etoposide (ICE) has synergistic activity in preclinical studies. This regimen has shown activity in metastatic breast cancer and non-small-cell lung cancer as well as platinum-resistant germ-cell tumors and metastatic GTD. This is the first report of a patient with a highly refractory GTD in whom brain metastasis developed while on chemotherapy, and whose brain metastasis went into remission with a low dose ICE regimen. Accordingly, ICE may be considered for patients with chemotherapy refractory GTD metastatic to the brain.
AB - Gestational trophoblastic disease (GTD) metastatic to the brain has a very poor prognosis with a survival rate of less than 25%, especially for patients in whom brain metastases develop while on or after chemotherapy. Cure can be achieved by chemotherapy alone. The regimen of etoposide, methotrexate, actinomycin-D, vincristine, and cyclophosphamide has shown encouraging results and is considered to be standard first-line treatment for high risk patients. For patients in whom this regimen fails, a salvage chemotherapy regimen is used. The combination of ifosfamide, carboplatin, and etoposide (ICE) has synergistic activity in preclinical studies. This regimen has shown activity in metastatic breast cancer and non-small-cell lung cancer as well as platinum-resistant germ-cell tumors and metastatic GTD. This is the first report of a patient with a highly refractory GTD in whom brain metastasis developed while on chemotherapy, and whose brain metastasis went into remission with a low dose ICE regimen. Accordingly, ICE may be considered for patients with chemotherapy refractory GTD metastatic to the brain.
KW - CNS metastasis
KW - ICE
KW - Refractory GTD
UR - http://www.scopus.com/inward/record.url?scp=9844255061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9844255061&partnerID=8YFLogxK
M3 - Article
C2 - 9443008
AN - SCOPUS:9844255061
SN - 0392-2936
VL - 18
SP - 453
EP - 456
JO - European journal of gynaecological oncology
JF - European journal of gynaecological oncology
IS - 6
ER -